JP4036494B2 - ウイルスを不活化した静脈内注射可能な免疫血清グロブリンの調製 - Google Patents

ウイルスを不活化した静脈内注射可能な免疫血清グロブリンの調製 Download PDF

Info

Publication number
JP4036494B2
JP4036494B2 JP26508496A JP26508496A JP4036494B2 JP 4036494 B2 JP4036494 B2 JP 4036494B2 JP 26508496 A JP26508496 A JP 26508496A JP 26508496 A JP26508496 A JP 26508496A JP 4036494 B2 JP4036494 B2 JP 4036494B2
Authority
JP
Japan
Prior art keywords
solution
aca
incubation
tnbp
antibody solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP26508496A
Other languages
English (en)
Japanese (ja)
Other versions
JPH09124507A5 (enExample
JPH09124507A (ja
Inventor
ウイリアム・アール・アロンソ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Original Assignee
Miles Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24120836&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4036494(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Miles Inc filed Critical Miles Inc
Publication of JPH09124507A publication Critical patent/JPH09124507A/ja
Publication of JPH09124507A5 publication Critical patent/JPH09124507A5/ja
Application granted granted Critical
Publication of JP4036494B2 publication Critical patent/JP4036494B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • A61L2/0088—Liquid substances
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP26508496A 1995-09-22 1996-09-17 ウイルスを不活化した静脈内注射可能な免疫血清グロブリンの調製 Expired - Lifetime JP4036494B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/532,211 US6686191B1 (en) 1995-09-22 1995-09-22 Preparation of virally inactivated intravenously injectable immune serum globulin
US532211 1995-09-22

Publications (3)

Publication Number Publication Date
JPH09124507A JPH09124507A (ja) 1997-05-13
JPH09124507A5 JPH09124507A5 (enExample) 2004-09-02
JP4036494B2 true JP4036494B2 (ja) 2008-01-23

Family

ID=24120836

Family Applications (1)

Application Number Title Priority Date Filing Date
JP26508496A Expired - Lifetime JP4036494B2 (ja) 1995-09-22 1996-09-17 ウイルスを不活化した静脈内注射可能な免疫血清グロブリンの調製

Country Status (10)

Country Link
US (1) US6686191B1 (enExample)
EP (2) EP1356829A3 (enExample)
JP (1) JP4036494B2 (enExample)
AT (1) ATE257016T1 (enExample)
AU (1) AU709608B2 (enExample)
CA (1) CA2185859C (enExample)
DE (1) DE69631229T2 (enExample)
DK (1) DK0764447T3 (enExample)
ES (1) ES2213760T3 (enExample)
PT (1) PT764447E (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998044948A2 (en) * 1997-04-07 1998-10-15 Cangene Corporation Intravenous immune globulin formulation containing a non-ionic surface active agent with improved pharmacokinetic properties
AT405608B (de) * 1997-04-08 1999-10-25 Immuno Ag Verfahren zur inaktivierung von pathogenen, insbesondere von viren, in einem biologischen material
BR9807936A (pt) 1997-04-08 2000-02-22 Baxter Ag Preparação farmacêutica imuno-tolerante de complexo de pró-trombina, processo para a produção de uma preparação, e, utilização de uma preparação
US6717116B1 (en) * 1999-08-10 2004-04-06 Ibiden Co., Ltd. Semiconductor production device ceramic plate
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
IL155002A0 (en) 2000-10-12 2003-10-31 Genentech Inc Reduced-viscosity concentrated protein formulations
KR100791502B1 (ko) * 2006-09-29 2008-01-03 한스바이오메드 주식회사 바이러스 불활화된 무세포 인체 이식재 생산방법
EP2077118A1 (en) * 2008-01-07 2009-07-08 Gwo Rei Biomedical Technology Corp. Clottable concentrate of platelet growth factors and preparation method thereof
TW201039854A (en) 2009-03-06 2010-11-16 Genentech Inc Antibody formulation
LT3345615T (lt) 2010-03-01 2020-02-10 Bayer Healthcare Llc Optimizuoti monokloniniai antikūnai prieš audinių faktoriaus kelio slopiklį (tfpi)
CN102357259A (zh) * 2011-07-28 2012-02-22 王珊珊 一种生物蛋白海绵及其制备方法
EP3981873A1 (en) 2012-06-29 2022-04-13 EMD Millipore Corporation Methods for inactivating viruses during a protein purification process
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4396608A (en) * 1981-08-24 1983-08-02 Cutter Laboratories Intravenously injectable immune serum globulin
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US4762714A (en) * 1986-04-08 1988-08-09 Miles Laboratories, Inc. Preparation of retrovirus-free immunoglobulins
GB8628104D0 (en) * 1986-11-25 1986-12-31 Connaught Lab Pasteurization of immunoglobin solutions
EP0523406B1 (en) * 1991-07-05 1998-12-09 Bayer Corporation Use of tri(n-butyl) phosphate at low pH in solutions of biologically active proteins for enhanced virucidal activity

Also Published As

Publication number Publication date
EP1356829A2 (en) 2003-10-29
DE69631229T2 (de) 2004-12-02
EP0764447B1 (en) 2004-01-02
EP0764447A2 (en) 1997-03-26
ATE257016T1 (de) 2004-01-15
AU6569096A (en) 1997-03-27
AU709608B2 (en) 1999-09-02
EP1356829A3 (en) 2003-12-17
CA2185859A1 (en) 1997-03-23
EP0764447A3 (en) 1997-07-30
ES2213760T3 (es) 2004-09-01
PT764447E (pt) 2004-04-30
CA2185859C (en) 2011-04-19
JPH09124507A (ja) 1997-05-13
US6686191B1 (en) 2004-02-03
DE69631229D1 (de) 2004-02-05
DK0764447T3 (da) 2004-05-03

Similar Documents

Publication Publication Date Title
EP0073371B1 (en) Intravenously injectable immune serum globulin and method of preparing same
JP6612182B2 (ja) 免疫グロブリン組成物を調製するためのプロセス
US4499073A (en) Intravenously injectable immune serum globulin
JP4036494B2 (ja) ウイルスを不活化した静脈内注射可能な免疫血清グロブリンの調製
US4165370A (en) Injectable gamma globulin
EP1084147B1 (en) Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
CA1341505C (en) Intravenously administered polyclonal immunoglobulin preparation containing igm and method of manufacture
US4216205A (en) Process of preparing a serum protein composition for intravenous application
US20010051708A1 (en) Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
KR960008653B1 (ko) γ-글로불린 주사용 액상 제제
CN115768789A (zh) 用于获得包含人血浆来源的免疫球蛋白m的组合物的方法
JPH0768144B2 (ja) 静脈内投与可能なＩｇＧ、ＩｇＡ及びＩｇＭ含有薬物の製造方法
JPH04346934A (ja) γ−グロブリンの液状製剤
JPS6016406B2 (ja) 静脈内に投与可能なガンマ・グロブリンの製造法ならびにそれにより調製したガンマ・グロブリン
JPH0525862B2 (enExample)
RU1693751C (ru) Способ получения иммуноглобулина для внутривенного введения со сниженной антикомплементарной активностью
JP2775097B2 (ja) 静注用免疫グロブリン製剤
JP2618643B2 (ja) 静注用免疫グロブリン製剤
JPH0375533B2 (enExample)
JPH0680586A (ja) 静脈内投与に適したガンマ・グロブリン製剤

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070517

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20070522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070820

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20071023

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20071030

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101109

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111109

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121109

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121109

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131109

Year of fee payment: 6

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term